NOVO — Juni 2025
-
Low start dose of Amgen experimental weight-loss drug limits side effects - https://www.reuters.com/business/healthcare-pharmaceuticals/low-start-dose-amgen-experimental-weight-loss-drug-limits-side-effects-2025-06-23/
-
China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds - https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-sciwinds-glp-1-shows-similar-weight-loss-novos-wegovy-study-finds-2025-06-21/ Reuters
-
Obesity drugs show promise for treating a new ailment: migraine https://www.nature.com/articles/d41586-025-01976-2 Nature
-
New Data Shows Just How Powerful the Next Weight-Loss Drugs May Be https://www.nytimes.com/2025/06/21/well/new-weight-loss-drugs.html New York Times (ikke noget, der ikke allerede er nævnt her på forum)
-
Lidt omtale fra weekenden. https://www.youtube.com/watch?v=ohGp7H3S0xM
-
Novo: Manglede aftalen med Hims&Hers den nødvendige omhu? https://proinvestor.com/boards/126965
-
ADA25: Lilly's muscle-sparing combo bests semaglutide alone https://firstwordpharma.com/story/5975574
-
Novo kritiseres af Hims & Hers-topchef efter endt samarbejde https://proinvestor.com/investornyt/1332370/novo-kritiseres-af-hims-hers-topchef-efter-endt-samarbejde
-
Marketwire er forvirret og forveksler situationen hvor Wegovy er udsolgt og salg af individuelle doseringer. Det er to ting som ikke har noget med hinanden at gøre. HIMS fortsætter at sælge individuelle doseringer som påskud for at sælge compound. Sagsøg dem !
-
Novo lancerer Wegovy i Indien https://proinvestor.com/investornyt/1332399/novo-lancerer-wegovy-i-indien
-
Novo genvinder en smule terræn efter afbrudt Hims & Hers-partnerskab https://proinvestor.com/investornyt/1332448/novo-genvinder-en-smule-terraen-efter-afbrudt-hims-hers-partnerskab
-
Novos opsagte partner trues af søgsmål fra investorer https://proinvestor.com/investornyt/1332545/novos-opsagte-partner-trues-af-sogsmal-fra-investorer
-
BrightGene Pharmaceutical reported upbeat mid-stage results for its investigational dual GLP-1/GIP agonist BGM0504, demonstrating superior glycaemic control over Novo Nordisk’s GLP-1 agonist Wegovy/Ozempic (semaglutide) in patients with type 2 diabetes, along with significant weight reduction in obese individuals. The data were presented at the American Diabetes Association (ADA) annual meeting. https://firstwordpharma.com/story/5975593
-
Novo-rival har store forventninger til ny vægttabspille https://proinvestor.com/investornyt/1332887/novo-rival-har-store-forventninger-til-ny-vaegttabspille
-
Eli Lilly og Novo Nordisk vil blive førende inden for lægemiddelsalg i 2030, vurderer analyse
Dataanalysevirksomheden Evaluate Pharma forudser, at Eli Lilly vil toppe listen over verdens førende lægemiddelsælgere i 2030, mens Novo Nordisk vil indtage en andenplads.
(medwatch.dk)
-
Hvordan påvirker den geopolitiske uro i Mellemøsten de globale aktiemarkeder? Ugens afsnit af Investeringspodcasten dykker ned i investorernes reaktioner og markedets udvikling.
I dette afsnit får du også:
Seneste nyt om Novo Nordisk: Ny data og afbrudt samarbejde
Indblik i Teslas robottaxi og hvad det kan betyde for aktien https://proinvestor.com/boards/127002 -
Health Rounds: Inhaled insulin as good as injection for children at mealtime - https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-inhaled-insulin-good-injection-children-mealtime-2025-06-25/ Reuters
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind